Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Checkpoint inhibitor and antiphospholipid syndrome in melanoma

Sanchez A et al. JAMA Derm. 2018 Sep 19. doi: 10.1001/jamadermatol.2018.2770

Publish date:: October 2, 2018

Key clinical point: Antiphospholipid syndrome appears to be an immune-related adverse event associated with anti-PD-1 therapy.

Major finding: A melanoma patient receiving pembrolizumab was diagnosed with antiphospholipid syndrome that resolved following discontinuation of that treatment.

Study details: Case report of a woman in her 60s with stage IIIB unresectable melanoma who was treated with pembrolizumab 2 mg/kg every 3 weeks.

Disclosures: The authors reported no conflicts of interest.

Read the article.

Citation:

Sanchez A et al. JAMA Derm. 2018 Sep 19. doi: 10.1001/jamadermatol.2018.2770.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Melanoma

Phase 1 study: Beta-blocker may improve melanoma treatment response,

‘Impressive’ results with neoadjuvant T-VEC in advanced melanoma,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Neoadjuvant immunotherapy combo produces high response rate in melanoma,

Vaccine regimen boosts immune response in malignant melanoma,